Small Molecule Industry Stocks($VRTX, $BMY, $PFE...) Surge with 7.58% Weekly Gains📈
The small-molecule drug category is defined by organic compounds that have a notably low molecular weight. This specific characteristic could make them more susceptible to generic competition compared to their larger, more intricate biologic drug counterparts. Companies such as Principia Biopharma Inc., Kadmon Holdings Inc., and Essa Pharma Inc. have pioneered the development of these small molecules and related drugs.
🌐Tickers in Industry - $VRTX, $BMY, $PFE, $ABBV, $EPIX, $TBPH, $MDGL
Swing Trader for Beginners: Trading in Markets Trending Down (TA&FA) - Annualized Return + 61%
Leading Companies in the Sector
Three companies that have distinguished themselves in this arena are:
- ABBVIE (NYSE:ABBV)
- Pfizer (NYSE:PFE)
- Bristol-Myers Squibb Co (NYSE:BMY)
Market Capitalization Snapshot
Within this industry, the average market capitalization sits at a robust $92.3B. The spectrum of valuations is expansive, ranging from $202.4M (as held by EPIX) to a towering $258.1B, the latter being attributed to ABBVIE.
Price Movement Dynamics
Stocks in this group have shown commendable resilience and strength in recent times. The past week saw an average price growth of 7.58%. Looking at a broader timeline:
- Monthly gains averaged at 4.56%.
- The past quarter registered a decline averaging -7.49%.
To break it down further:
- EPIX led the charge with a staggering price ascent of 67.52%.
- Conversely, MDGL lagged behind, dipping by -6.29%.
Key price events include:
- Vertex Pharmaceuticals (VRTX, $374.01): Ascended with a weekly gain of +5.3% on 10/17/23.
- Pfizer (PFE, $33.94): Encountered a setback, declining by -5.14% during the week of 9/12/23.
- Bristol-Myers Squibb (BMY, $61.41): Also witnessed a weekly drop of -5.06% around 7/29/23.
Volume Activity Analysis
Volume plays a pivotal role in stock market dynamics. For stocks in this category:
- The weekly average volume growth was a substantial 484.72%.
- Monthly growth in trade volume averaged at 456.79%.
- On a quarterly basis, the volume growth averaged an impressive 818.55%.
A notable volume event was observed for Madrigal Pharmaceuticals on 12/23/22, where trading activity soared, surpassing its 65-Day Volume Moving Average by a hefty 220%.
💼Fundamental Analysis Metrics
In assessing the intrinsic value and potential of stocks, fundamental analysis ratings are invaluable. For the companies under this theme, a score closer to 1 indicates optimistic prospects, while nearing 100 implies less favorable projections.
The small molecule industry's recent performance underscores its evolving dynamics and growth potential. As the industry continues to develop and mature, close observation of market indicators will be crucial for discerning future trajectories.
VRTX : On October 20, 2023, the Stochastic Oscillator for VRTX exited the overbought region, potentially signaling a bearish trend. Historical analysis by A.I.dvisor revealed that in 36 out of 65 similar scenarios, the stock trended downward, indicating a 55% likelihood of VRTX's price declining. Investors might contemplate reassessing their positions in light of this shift.
BMY : On October 11, 2023, BMY's RSI Indicator emerged from the oversold zone, hinting at a possible upward momentum shift. Historical data from A.I.dvisor, after examining 34 comparable events, showed that in 26 instances the stock experienced an upward trend. This suggests a 76% chance of BMY's stock price ascending. Investors might consider purchasing the stock or exploring call options based on this trend reversal.
PFE : On October 13, 2023, PFE's Momentum Indicator slipped below the 0 mark, suggesting a potential onset of a downward trend. Investors might ponder divesting their shares or examining put options. Analyzing 81 analogous situations, Tickeron's A.I.dvisor found that in 56 cases, the stock further depreciated in subsequent days. This translates to a 69% likelihood of PFE continuing its downward trajectory.
VRTX's Stochastic Oscillator stays in oversold zone for 1 day
Be on the lookout for a price bounce soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +1.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where VRTX advanced for three days, in 241 of 367 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
VRTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VRTX as a result. In 41 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 47%.
The Moving Average Convergence Divergence Histogram (MACD) for VRTX turned negative on October 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 59 similar instances when the indicator turned negative. In 26 of the 59 cases the stock turned lower in the days that followed. This puts the odds of success at 44%.
VRTX moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for VRTX crossed bearishly below the 50-day moving average on October 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 37%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VRTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 42%.
The Aroon Indicator for VRTX entered a downward trend on October 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 20 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 32 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 41 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. VRTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.605) is normal, around the industry mean (26.780). P/E Ratio (30.732) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (1.939) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (10.449) is also within normal values, averaging (438.009).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company that discovers and develops novel, small molecule pharmaceuticals
Industry Biotechnology
Advertisement